drugset / Trial / NCT00699049

A Study Comparing the Efficacy of an Alpha Blocker Versus an Alpha Blocker Plus Solifenacin in Men With Overactive Bladder

NCT00699049

Phase 4 Completed 94 enrolled KYU-SUNG LEE Astellas Pharma Korea, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to explore additional benefit of solifenacin after 12-week treatment, compared with alpha blocker monotherapy in men with residual OAB symptoms.

Timeline

Start
2008-06
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Solifenacin Small molecule Oral

Indications